zacks.com · 19 jun

Bruker Gains 50.3% in a Year: What's Driving the Rally?

BRKR's rally is fueled by BSI NANO growth, AI-driven metrology demand and gains in preclinical imaging despite tariff pressures.

forbes.com · 17 jun

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

gurufocus.com · 15 jun

Bruker Corp (BRKR) Stock Up 4.4% and Still Undervalued -- GF Score: 85/100

On June 15, 2026, Bruker Corp (BRKR) shares rose 4.4% to a current price of $56.63. The stock has shown remarkable performance within the past year, with a 48.7

seekingalpha.com · 8 jun

Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

marketbeat.com · 6 jun

Bruker Signals Growth Pivot as Semiconductor and Overseas Orders Gain Steam

Bruker NASDAQ: BRKR is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies healthcare conference.

zacks.com · 5 jun

Bruker (BRKR) Up 37.1% Since Last Earnings Report: Can It Continue?

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

fool.com · 4 jun

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.

businesswire.com · 4 jun

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)---- $BRKR #BRKR--At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by.